Clinical trials: Sweating
Hidradenitis Suppurativa (HS)
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
- Trial name
- COMPASS 2-HS (NCT07287644)
- Testing
- BFB759
- Where
- 64 sites in United States, Bulgaria and 5 more
- Volunteers
- 210 people
- Sponsor
- Bluefin Biomedicine, Inc.
Primary Axillary Hyperhidrosis
Investigation of Ascending Concentrations of Glycopyrronium Bromide (GPB) in a Topical Formulation in Subjects With Axillary Hyperhidrosis
The aim of the study is to assess the safety, tolerability, pharmacokinetics (PK) and efficacy of escalating concentrations of GPB in subjects with axillary hyperhidrosis.
- Trial name
- NCT03037788
- Testing
- WO3979, WO3970, WO3992
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Hidradenitis Suppurativa (HS)
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label…
- Trial name
- TibuSHIELD (NCT06993610)
- Testing
- Tibulizumab Dose A, Tibulizumab Dose B
- Where
- 61 sites in United States, Canada and 4 more
- Volunteers
- 247 people
- Sponsor
- Zura Bio Inc
Hidradenitis Suppurativa
A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate the clinical efficacy of bermekimab in participants with moderate to severe Hidradenitis Suppurativa (HS).
- Trial name
- LYRA (NCT04988308)
- Testing
- Bermekimab, Adalimumab
- Where
- 54 sites in United States, Australia and 6 more
- Volunteers
- 151 people
- Sponsor
- Janssen Research & Development, LLC
Crohn Disease, Ulcerative Colitis
The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.
The purpose of the Phase IV study is to investigate the effects of both Volume and Citrate on Injection Site Pain (ISP), adherence, patient satisfaction, Quality of Life, and Disease Assessment in the Canadian Adalimumab Market.
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- EASE PAIN (NCT05913817)
- Testing
- AVT02 (Alvotech Biosimilar to Adalimumab)
- Where
- Canada
- Volunteers
- 324 people
- Sponsor
- Jamp Pharma Corporation
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa
The main purpose of this study is to evaluate the efficacy and safety of AVTX-009 compared with placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).
- Trial name
- LOTUS (NCT06603077)
- Testing
- AVTX-009 Regimen 1, AVTX-009 Regimen 2
- Where
- 89 sites in United States, Australia and 11 more
- Volunteers
- 253 people
- Sponsor
- Avalo Therapeutics, Inc.
Hidradenitis Suppurativa (HS)
Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
This is a post-approval commitment study to evaluate efficacy, and safety of two dosing regimens of secukinumab (AIN457), 300 mg every four weeks (Q4W) and every two weeks (Q2W), in Chinese adult patients with moderate to severe…
- Trial name
- NCT07489573
- Testing
- Secukinumab
- Where
- 10 sites in China
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Heart Failure
Effect of Enhanced Sweat Rate on the Safety and Edema Status of Chronic Edematous Patients
The purpose of this study is to demonstrate safety and performance of AquaPass System for enhancing fluid transfer through the skin, by increased sweat rate, in edematous patients.
- Trial name
- NCT04578353
- Testing
- The AquaPass System
- Where
- Israel
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- AquaPass Medical Ltd.
Hidradenitis Suppurativa (HS)
A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab
This study is open to people with hidradenitis suppurativa (HS) who have completed another study with spesolimab (study 1368-0098 (NCT05819398) or study 1368-0100).
- Trial name
- NCT06241573
- Testing
- Spesolimab
- Where
- 36 sites in United States, Argentina and 12 more
- Volunteers
- 39 people
- Sponsor
- Boehringer Ingelheim
Hyperhidrosis, Axillary Hyperhidrosis
miraDry Post Market Tumescent Anesthesia Study
This clinical trial will collect data on the safety and efficacy of the miraDry treatment when High Volume Anesthesia (Tumescent Anesthesia) is used as an alternate method of anesthetizing the axilla prior to the miraDry System…
- Trial name
- NCT05546710
- Testing
- miraDry treatment
- Volunteers
- healthy volunteers welcome
- Sponsor
- miraDry, Inc.
Sweat Rate
Normative Data for Sweating Rate, Sweat Sodium Concentration and Sweat Sodium Loss in Female Athlete
The main objectives are to determine sweat sodium concentration [Na+], whole body sweat rate (WBSR) and rate of sweat sodium loss (RSSL) in female athletes aged 13 and above during their normal planned training session across…
- Trial name
- NCT06995768
- Testing
- Sweat patch
- Where
- United States
- Volunteers
- 516 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Hidradenitis Suppurativa
A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial
This study is open to adults with hidradenitis suppurativa who took part in a previous clinical study of a medicine called spesolimab. Participants who completed treatment can join this study.
- Trial name
- NCT04876391
- Testing
- Spesolimab 1200 mg, Spesolimab 600 mg
- Where
- 26 sites in United States, Australia and 10 more
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Hyperhidrosis
A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
To assess the safety and efficacy of 3 doses of BBI-4000 and vehicle (4 treatment arms), when applied once a day for 4 weeks, for the treatment of axillary hyperhidrosis.
- Trial name
- NCT02336503
- Testing
- BBI-4000 Gel, 5%, BBI-4000 Gel, 10%, BBI-4000 Gel, 15%
- Where
- 12 sites in United States
- Volunteers
- 189 people
- Sponsor
- Botanix Pharmaceuticals
Hyperhidrosis
A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis
This is a three-year study in subjects with axillary hyperhidrosis involving injection of Botulinum Toxin Type A into the axilla to reduce sweating.
- Trial name
- NCT00168402
- Testing
- Botulinum Toxin Type A
- Volunteers
- 193 people
- Sponsor
- Allergan
Hidradenitis Suppurativa
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- NCT06799000
- Testing
- Remibrutinib Dose A, Remibrutinib Dose B
- Where
- 139 sites in United States, Argentina and 18 more
- Volunteers
- 588 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically
The objective of this study was to assess the safety and efficacy of adalimumab prior to surgery in participants with moderate to severe Hidradenitis Suppurativa (HS) who were surgical candidates.
- Trial name
- SHARPS (NCT02808975)
- Testing
- Adalimumab
- Where
- 55 sites in United States, Belgium and 21 more
- Volunteers
- 206 people
- Sponsor
- AbbVie
Primary Focal Hyperhidrosis, Axilla
Efficacy and Safety of the DTS-G2 System in Patients With Axillary Hyperhidrosis
This is a prospective, multi-center, parallel, randomized, blinded study. The study has two groups, where in one study group the subjects receive treatment for axillary hyperhidrosis (excessive underarm sweating) with the DTS-G2…
- Trial name
- DRI-UP (NCT00931359)
- Testing
- DTS-G2 System
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- Miramar Labs
Hyperhidrosis
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis
This is a safety and efficacy study of botulinum toxin type A in subjects with primary axillary hyperhidrosis.
- Trial name
- NCT02565732
- Testing
- Botulinum toxin type A
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Revance Therapeutics, Inc.
X-Linked Hypohidrotic Ectodermal Dysplasia
Sweat Duct Imaging in Mother/Newborn Dyads
The purpose of this study is to evaluate sweat duct number on the plantar surface of newborn infants using a non-invasive confocal microscopy device.
- Trial name
- NCT01342133
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Edimer Pharmaceuticals